Cholesterol is associated with stroke, but is not a risk factor

Stroke

Volumn 35, Issue 6, 2004, Pages 1524-1525

  Thrift, Amanda G ^a  

^a HEIDELBERG REPATRIATION HOSPITAL   (Australia)

Author keywords

Cholesterol; Risk factors; Stroke

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STATINE DERIVATIVE;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; HUMAN; INFLAMMATION; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY; STROKE; THROMBOSIS;

CEREBROVASCULAR ACCIDENT; CHOLESTEROL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK FACTORS;

EID: 2542548280     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000128590.48495.02     Document Type: Short Survey

References (10)

1. Beaglehole R, Bonita R, Kjellström T. Basic Epidemiology. Geneva: World Health Organization; 1993.
2. Qizilbash N, Duffy SW, Warlow C, Mann J. Lipids are risk factors for ischaemic stroke: overview and review. Cerebrovasc Dis. 1991;2: 127-136.
3. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts. Lancet. 1995;346:1647-1653.
4. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423-1429.
5. Zhang X, Patel A, Horibe H, Wu Z, Barzi F, Rodgers A, MacMahon S, Woodward M. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol. 2003;32:563-572.
6. Engström G, Lind P, Hedblad B, Stavenow L, Janzon L, Lindgärde F. Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men. Circulation. 2002; 105:2632-2637.
7. Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch Intern Med. 2003;163:669-676.
8. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998;279: 1643-1650.
9. MacMahon S, Sharpe N, Gamble G, Hart H, Scott J, Simes J, White H. Effects of lowering average or below-average cholesterol levels on the progression of carotid atherosclerosis: results of the lipid atherosclerosis substudy. LIPID Trial Research Group. Circulation. 1998;97:1784-1790.
10. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Östergren J, for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.